Dermatology update: Ensuring the safe and effective use of topical JAK inhibitors in pharmacy practice

For Canadian pharmacists, understanding the pharmacologic nuances and real-world applications of topical JAK inhibitors is essential for optimizing patient care, addressing safety concerns, and supporting adherence through individualized, evidence-based counselling.

Authors: Pharmacist Réjean Lemay, and dermatologists Dr. Wayne Gulliver and Dr. Kim Papp

Accredited for 1.25 CEUs by the Canadian Council on Continuing Education in Pharmacy; CCCEP #1329-2025-4018-I-P

Learning objectives:
 

Upon successful completion of this continuing education lesson, participants should  be better able to:

• Describe the role of the JAK-STAT pathway in the pathophysiology of atopic dermatitis and vitiligo.
• Differentiate the safety profiles of topical vs systemic JAK inhibitors, as well as understand the nature and derivation of boxed warnings.
• Identify Health Canada–approved topical JAK inhibitors and describe their indications, dosage, safety considerations, and counselling points.
• Provide evidence-informed counselling on the safe and effective use of topical JAK inhibitors, including adherence strategies and adverse effect education.

This learning activity is supported by educational funding from Incyte Bioscences Canada.